Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects

Inclusion Criteria: * Patient with confirmed HIV infection * Age ≥ 18 years * Written informed consent * Male patient or non-pregnant, non-lactating female * No previous treatment with any antiretroviral drugs * HIV-1 RNA \> 1000 copies/ml * Indication to start an antiretroviral treatment as long as subject has also a CD4 cell count ≤ 500/mm3 either at screening or on a sample taken within 3 months before screening * No major IAS-USA mutations on genotypic testing at the screening visit or on any historical genotype, if available Non-inclusion Criteria: * Woman without effective contraception method (recommended contraception during the trial is mechanical + a second method other than an oral contraceptive) * Pregnant or breastfeeding woman * Woman expecting to conceive during the study * HIV-2 co-infection * Creatinine clearance \< 60 ml/mn (Cockcroft \& Gault equation), alkaline phosphatase, ASAT, or ALAT ≥ 5 ULN * Patient with significant impairment of hepatic function, defined as serum albumin \< 2.8 g/dl or INR \> 1.7 or presence of ascites, in the absence of another explanation for the abnormal finding * CD4 \> 500/mm3 at screening, except in case of symptomatic HIV disease (defined by conditions qualifying for CDC category B or C) or CD4 ≤ 500/mm3 on a sample taken within 3 months before screening. * Any major IAS-USA mutation conferring resistance to one or more of reverse transcriptase or protease inhibitors on genotypic testing at screening * Mycobacteriosis under treatment * Malignancy requiring chemotherapy or radiotherapy * Positive HBs Ag * HCV infection for which specific treatment is ongoing or planned during the first year on trial treatment * Known hypersensitivity to one of the trial drugs or its excipients * Contraindicated concomitant treatment * Anticipated non-compliance with the protocol * Participation in another clinical trial with an on-going exclusion period at screening * Subject under legal guardianship or incapacitation * Subject, who in the opinion of the investigator, is unable to complete the study period